Screener
Celldex Therapeutics CLDX Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsAndOtherReceivablesNetCurrent.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
FAQ
- What is Celldex Therapeutics's accounts receivable?
- Celldex Therapeutics (CLDX) reported accounts receivable of $230K in Q2 2026.
- How has Celldex Therapeutics's accounts receivable changed year-over-year?
- Celldex Therapeutics's accounts receivable increased by 155.6% year-over-year, from $90K to $230K.
- What is the long-term trend for Celldex Therapeutics's accounts receivable?
- Over 5 years (2020 to 2025), Celldex Therapeutics's accounts receivable has grown at a 2.3% compound annual growth rate (CAGR), from $1.8M to $2.02M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Celldex Therapeutics's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude